GENFIT : ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
130
GENFIT : ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING OF JUNE 15, 2018 - AVAILABILITY OF PREPARATORY DOCUMENTS

GENFIT: ordinary and extraordinary SHAREHOLDERS' meeting of june 15, 2018 - AVAILABILITY OF PREPARATORY DOCUMENTS

Lille (France), Cambridge (Massachusetts, United States), May 9, 2018 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced the that it has published today in today's French legal announcements bulletin ( Bulletin des Annonces Légales Obligatoires ) its convening notice to the Ordinary and Extraordinary Shareholders' Meeting to be held on Friday, June on June 15, 2018, at 2:30pm, at the Faculty of Pharmaceutical & Biological Sciences of Lille, located Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.

All documentation regarding this Shareholders' Meeting is available to shareholders in accordance with existing regulations, and is available on the Company's website, in the documentation center ( http://www.genfit.com/investors/documentation-center/ ).

Documents listed in Article R.225-83 of the French commercial code are available to shareholders in accordance with existing regulations.

For this 2018 Ordinary and Extraordinary Shareholders' Meeting, the Company will allow shareholders to send their voting instructions via Internet through the VOTACCESS platform.  The Company has made available in the documentation center of its website a tutorial to familiarize its shareholders with this new tool for online voting.

More generally, shareholders are invited to contact the toll-free (France only) number starting Monday, May 14, 2018, with any questions regarding how to participate in the Meeting: 0800 940 651

About GENFIT

GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) and more generally the gastro-intestinal arena. GENFIT's approach combines novel treatments and biomarkers. Its lead proprietary compound, elafibranor, is currently in a Phase 3 study. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 130 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT - ISIN: FR0004163111). www.genfit.com

Forward Looking Statement / Disclaimer This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, including related to biomarkers, progression of, and results of clinical data from, the RESOLVE-IT trial and the trial of elafibranor in PBC, review and approvals by regulatory authorities, such as the FDA or the EMA, regarding in particular, elafibranor in NASH and PBC, as well as other drug candidates in other indications and biomarkers candidates, the success of any inlicensing strategies, the Company's continued ability to raise capital to fund its development, as well as those discussed or identified in the Company's public filings with the AMF, including those listed under Section 4 "Main Risks and Uncertainties" of the Company's 2017 Registration Document registered with the French Autorité des marchés financiers on April 27, 2018 under n° R.18-032, which is available on GENFIT's website ( www.genfit.com ) and on the website of the AMF ( www.amf-france.org ). Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

CONTACT

GENFIT | Jean-François Mouney - Chairman & CEO | +333 2016 4000

PRESS RELATIONS | Bruno Arabian | +336 8788 4726

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 38

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 71

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 301

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 36

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 105

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 23

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
The Melt Grabs Top Spot in Burger Ratings War

Updated Category News Views 5

Burger Battle: The Melt Claims Victory When you're in the cutthroat world of fast-casual dining, grabbing the top spot on any list is no small potatoes. The Melt did just that, snatching the title of America’s Highest-Rated Burger Spot. Based on an in-depth analysis of Google and Yelp reviews, folks have spoken, loud and clear, over the past two years. It's a world...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 92

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading

Top 5 Most Recently Viewed Articles

Customers Bancorp, Inc. Faces Class Action Lawsuit

Updated Category News Views 179

Introduction to the Class Action Lawsuit Against Customers Bancorp Recently, Customers Bancorp, Inc. found itself at the center of a significant legal challenge. A securities class action lawsuit has been initiated in federal court on behalf of investors who purchased or acquired shares of Customers Bancorp, Inc. (NYSE: CUBI) during a specific time frame. This action...

Continue Reading
Projected Growth in the Aluminum Beverage Can Industry

Updated Category News Views 238

Exploring the Future of the Aluminum Beverage Can Market As the aluminum beverage can industry steers toward a monumental future, it's evident that the market has grown significantly, evolving to meet the rising demand for sustainable and practical packaging solutions. With a valuation of US$ 36.95 billion in 2024, projections indicate a remarkable increase to US$ 61.12...

Continue Reading
Cybersecurity Initiative Launches for Global Nonprofit Protection

Updated Category News Views 87

Global Leaders Unite for Nonprofit Cybersecurity Influential figures from various sectors gathered at the historic Peace Palace to advocate for better cybersecurity within the nonprofit sector. This initiative, known as 'BEYOND125, Securing Our World's Digital Future,' is focused on tackling significant cybersecurity challenges faced by millions of organizations around...

Continue Reading
Guarda Wallet's Gas-Free USDT Revolution on Tron

Updated Category News Views 44

The Frictionless Future of USDT on the Tron Network You know, it seems like every few months we hear about some innovation that's going to 'revolutionize' crypto transactions. But here's something that's actually shifting the gears—a practical workaround for a typical problem faced by the average Joe trading in stablecoins. Welcome to Guarda Wallet's gas-free...

Continue Reading
Ultragenyx and Mereo BioPharma Stocks Face Significant Decline

Updated Category News Views 130

Overview of Current Situation Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) saw their stock values significantly drop recently, causing concern among investors. The decline comes in light of new developments from their ongoing clinical trials for a drug targeting a rare genetic disorder. What Unfolded? The duo announced updates...

Continue Reading